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OBJECTIVES The aim of our study was to investigate coronary vascular kinin receptor function in patients
with atherosclerosis or its risk factors.
BACKGROUND Although acetylcholine (ACH) is used as a probe for testing vascular function in vivo,
endogenous bradykinin (BK) regulates resting and flow-mediated epicardial tone.
METHODS In 53 patients with mild atherosclerosis or its risk factors and 9 control subjects, endothelium-
dependent vasomotion was tested with intracoronary ACH (30 mg/min) and BK (62.5
ng/min and 4 mg/min), and endothelium-independent function with sodium nitroprusside.
Metabolic vasodilation was assessed during cardiac pacing (n 5 19). Correlation with serum
angiotensin-converting enzyme (ACE) levels and the ACE insertion/deletion genotype was
performed.
RESULTS There was progressive impairment in ACH-mediated microvascular dilation with increasing
numbers of risk factors (p 5 0.025, analysis of variance). By contrast, BK- and sodium
nitroprusside-mediated microvascular dilation was similar in all groups. Similarly, there was
no correlation between epicardial coronary responses to ACH and BK; segments that
constricted or dilated with ACH had similar dilator responses with BK. Bradykinin, but not
ACH-mediated vasomotion, was depressed in epicardial segments that constricted with
pacing. Finally, epicardial BK responses were depressed in patients with high ACE levels and
in those with the ACE DD genotype.
CONCLUSIONS Endothelial dysfunction in atherosclerosis appears to be receptor-specific, involving the
muscarinic receptor with relative sparing of the kinin receptor pathways. Abnormal reactivity
of epicardial coronary arteries during physiologic stress is better represented by BK and not
by ACH responses. Bradykinin activity and, hence, physiologic coronary vasomotion appears
to be influenced by serum ACE levels and the ACE insertion/deletion genotype. (J Am Coll
Cardiol 2000;36:1467–73) © 2000 by the American College of Cardiology
The endothelium regulates vascular smooth muscle tone by
releasing a variety of dilating and constricting factors in
response to neural, humoral and autocrine stimulation.
Important endothelium-dependent relaxing agents include
nitric oxide (NO), prostacyclin and endothelium-derived
hyperpolarizing factor. In the human coronary circulation,
NO contributes to resting tone and to flow-mediated
dilation, but these functions are perturbed in patients with
atherosclerosis or in the presence of risk factors such as
hypercholesterolemia, hypertension, diabetes mellitus and
smoking (1–3). The resulting endothelial dysfunction pro-
motes paradoxical epicardial constriction and depressed
microvascular dilation that may accentuate myocardial isch-
emia. However, the precise mechanisms leading to defective
endothelial function and vasomotion remain unclear.
Recent data indicate an important role for the vascular
kallikrein-kinin system, in particular of bradykinin (BK) in
the regulation of vascular function (4). Bradykinin is a
nonapeptide generated from kininogen by the action of
kallikreins and is rapidly degraded by kininases such as
angiotensin-converting enzyme (ACE) (5). Endothelial and
vascular smooth muscle cells tonically generate BK that has
important autocrine and paracrine functions (5). At least
two types of kinin receptors, termed B1 and B2, have been
identified in vascular tissue, though the vasodilator action of
BK is largely believed to be mediated by endothelial kinin
receptors (6) via promotion of NO, prostacyclin and hyper-
polarizing factor release (7–9).
Because BK regulates resting tone and flow-mediated
epicardial vasodilation in human coronary arteries (4,10), we
hypothesized that abnormal flow-mediated vasomotion in
patients with atherosclerosis and its risk factors results from
an abnormality in kinin receptor function or in its signal
transduction pathways. Furthermore, because BK is metab-
olized by ACE and tissue ACE activity is at least partially
regulated genetically by the ACE insertion/deletion (I/D)
polymorphism, it is possible that the action of BK on the
vascular wall will be influenced by this genetic footprint
(11).
Thus, the aim of our study was to investigate whether
coronary vascular kinin receptor function: a) correlates with
endothelial muscarinic receptor function in patients with
atherosclerosis or its risk factors, thus reflecting generalized
impairment of receptor-mediated NO release, b) correlates
with flow-mediated epicardial vasomotion, and c) is influ-
enced by serum ACE levels or the ACE I/D gene polymor-
phism. We also assessed whether BK-mediated coronary
vasodilation is NO-mediated.
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METHODS
Patients. We studied 53 patients—34 with coronary ath-
erosclerosis and 19 with normal coronary arteries and risk
factors for atherosclerosis who were undergoing diagnostic
cardiac catheterization for investigation of chest pain or
abnormal noninvasive tests. The control group included
nine patients with angiographically normal coronary arteries
without risk factors who had noncardiac chest pain (that is,
normal angiogram and noninvasive tests). Risk factors
predisposing to endothelial dysfunction were defined as the
presence of hypertension (blood pressure . 140/90 mm Hg),
hypercholesterolemia (low-density lipoprotein . 160 mg/dL),
diabetes, current smoking or smoking in the previous year and
angiographic evidence of atherosclerosis (Table 1). There were
41 (66%) men. Patients with recent myocardial infarction,
valvular heart disease, symptomatic heart failure or those
treated with ACE inhibitors in the previous two weeks were
excluded. The study was approved by the National Heart,
Lung, and Blood Institute Investigational Review Board, and
informed consent was obtained from all patients.
Protocol. All cardiac medications were withdrawn at least
48 h before the study, and aspirin or other cyclooxygenase
inhibitors were discontinued seven days before. After diag-
nostic coronary angiography was performed, a 6F guide
catheter was introduced into the proximal segment of a
coronary artery, and blood flow velocity was measured using
a 0.018 inch (0.014 inch with infusion catheters) wire
equipped with a Doppler crystal at its tip (Cardiometrics
Flowire, Cardiometrics, Endosonics Corp., Rancho Cor-
dova, California). The coronary artery infusion protocol and
the measurement of coronary artery blood flow, resistance
and diameter were performed as described previously (2,3).
RESPONSE TO PACING. After a 5-min infusion of dextrose
5% at 1 ml/min, measurement of coronary blood flow
velocity and coronary angiography were performed and
repeated after each intervention. In 19 patients with risk
factors for endothelial dysfunction, we performed cardiac
pacing to study the effects of increased flow (shear stress) on
coronary epicardial vessels. Rapid atrial pacing was per-
formed in 17 patients at heart rates ranging between 130 to
150 beats/min. Pacing from the right ventricle was per-
formed at 150 beats/min in the remaining two patients who
developed atrioventricular Wenckebach at rates below
115 beats/min. Thus, the mean cardiac pacing rate was
144 6 7 beats/min.
RESPONSE TO ACETYLCHOLINE, BK AND SODIUM NITRO-
PRUSSIDE (SNP). In all patients endothelium-dependent va-
sodilation was estimated by measuring coronary flow and
epicardial responses to incremental infusions of intracoro-
nary acetylcholine (ACH) starting at 3 mg/min in athero-
sclerotic patients followed by infusion at 30 mg/min for
2 min each. Normal controls were given the 30 mg/min dose
of ACH. This regimen avoided excessive constriction that
may occur at higher doses of ACH in atherosclerotic
coronary arteries.
Ten minutes after ACH testing and repeat baseline
measurements ensuring that the blood flow velocity had
returned to the previous baseline, responses to BK were
assessed. In a preliminary dose-finding study, we infused
BK at 62.5 ng/min, 0.25 mg/min, 1 mg/min and 4 mg/min
for 2 min each to demonstrate that there was progressive
vasodilation at all these doses with greater change at 4
mg/min compared with the 1 mg/min dose. Coronary blood
flow increase at the 4 mg/min dose of BK was in the range
of that observed with ACH. Therefore, for the study we
employed the 62.5 ng/min and 4 mg/min. The sequence in
which ACH and BK were infused was randomized.
Once blood flow velocity had returned to its baseline
value, endothelium-independent function was estimated
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme inhibitor
ACH 5 acetylcholine
ANOVA 5 analysis of variance
BK 5 bradykinin
BP 5 blood pressure
I/D 5 insertion/deletion
L-NMMA 5 L-NG monomethyl arginine
NO 5 nitric oxide
SNP 5 sodium nitroprusside
Table 1. Patient Characteristics
Variables Controls
Risk Factors
1 2 3 or More
Number 9 21 17 15
Men 4 14 13 10
Age (yrs) 45 6 3 53 6 2 54 6 3 51 6 2
LDL (mg/dL) 132 6 7 130 6 7 170 6 12* 173 6 10†
HDL (mg/dL) 44 6 5 41 6 3 41 6 4 40 6 3
Hypertension (n [%]) 0 6 (29) 9 (53) 13 (87)
Diabetes (n) 0 1 1 7
Smokers (n) 0 2 2 8
Atherosclerosis (n [%]) 0 7 (33) 12 (71) 15 (100)
Plasma ACE (U/L) 10.8 6 1.7 9.9 6 1 10.4 6 1.2 10.8 6 1.2
*p , 0.05; †p , 0.01 compared with controls.
ACE 5 angiotensin-converting enzyme inhibitor; HDL 5 high-density lipoprotein; LDL 5 low-density lipoprotein.
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with intracoronary sodium nitroprusside (SNP) given at
40 mg/min for 3 min, and flow reserve was measured with
intracoronary adenosine administered at 2.2 mg/min for
2 min.
EFFECTS OF L-NMMA. To compare the contribution of NO
to the effects of ACH and BK, repeat baseline measure-
ments were made in 20 patients after a 10-min interval
while continuing dextrose 5% infusion. This was followed
by a 10-min infusion of L-NG monomethyl arginine (L-
NMMA, Clinalfa AG, Switzerland), a specific inhibitor of
NO synthesis from L-arginine, at 64 mmol/min (1 ml/min).
This dose has previously been shown to significantly inhibit
NO-dependent responses to pharmacological and physio-
logical stimuli in humans (2,3). While continuing the
infusion of L-NMMA at 64 mmol/min, ACH (30 mg/min)
and, 10 min later, BK (62.5 ng/min and 4 mg/min) were
readministered for 2 min each.
Determination of ACE genotypes. Angiotensin-
converting enzyme genotyping was performed by laboratory
personnel blinded to the endothelial function data.
Angiotensin-converting enzyme genotypes were determined
by use of polymerase chain reaction according to previously
published protocols (12,13).
Statistical analysis. Data are expressed as mean 6 SEM.
Differences between means were compared by using paired
or unpaired Student t test, as appropriate. All p values were
two-tailed, and a value ,0.05 was considered to be of
statistical significance. Dose response curves were compared
by analysis of variance (ANOVA) using the SAS software
(SAS Institute; Cary, North Carolina). If the F value was
significant, a Bonferroni multiple comparison test was
performed. Correlation analysis was performed using Pear-
son’s correlation coefficient.
RESULTS
Hemodynamic changes. The 30 mg/min dose of ACH
was tolerated by all patients, did not alter systemic blood
pressure (BP), and was, therefore, used for comparing
vasomotor responses between groups. Bradykinin did not
alter systemic BP at the 62.5 ng/min dose, but at the 4
mg/min dose, a mild decrease was observed: 110 6 2 to
107 6 15 mm Hg, p 5 0.01. Intracoronary SNP signifi-
cantly reduced BP from 110 6 2 to 102 6 2 mm Hg, p ,
0.001.
Effect of risk factors on the responses to ACH, BK, SNP
and adenosine. CORONARY MICROVASCULAR FUNCTION.
There was a correlation between the response to ACH and
BK at the higher, but not the lower, dose of BK (Fig. 1) (r 5
0.33, p 5 0.007 for % change in flow ACH vs. BK, 4
mg/min). Patients with ACH-mediated microvascular dila-
tion in the lowest tertile also had reduced BK-mediated
dilation, and vice versa. To further investigate endothelium-
dependent and independent responses, we compared pa-
tients without (control group) to those with risk factors.
Baseline heart rate, coronary blood flow and resistance in
the control group were similar to patients with risk factors.
However, there was progressive impairment in ACH-
mediated microvascular dilation with increasing numbers of
risk factors (p 5 0.025, ANOVA, Fig. 2). By contrast,
BK-mediated microvascular dilation was similar at both
doses in controls and in patients with risk factors (p 5 0.5,
ANOVA, Fig. 3). Similarly, endothelium-independent di-
lation with SNP was not significantly altered in patients
with, compared to those without, multiple risk factors (p .
0.1, ANOVA, Fig. 2).
We also corrected the vasodilation in response to the two
endothelium-dependent dilators with the response to SNP.
The ratio of ACH:SNP-induced dilation in controls was
106 6 9%, compared with 73 6 6% in patients with risk
Figure 1. Comparison of BK and ACH-induced microvascular dilation.
Bars represent patients from the three tertiles of ACH responses: low
(,70%, n 5 23), medium (70–130%, n 5 23) and high (.130%, n 5 22)
increase in blood flow compared with baseline.
Figure 2. Effect of risk factors on ACH (30 mg/min) and SNP (40 g/min)
induced coronary microvascular dilation measured as % change in coronary
vascular resistance compared with baseline. *p , 0.05, **p # 0.01
compared with 0 risk factors. By analysis of variance, p 5 0.025 for ACH
and p . 0.1 for SNP responses between groups.
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factors (p 5 0.04). By contrast, the ratio of BK:SNP-
induced dilation in controls (106 6 9%) was similar to
patients with risk factors (104 6 5%, p 5 NS). Flow reserve
with adenosine was similar in controls and patients with
multiple risk factors: reduction in coronary vascular resis-
tance of 77 6 3% and 73 6 1%, respectively, p 5 0.24.
CORONARY EPICARDIAL FUNCTION. Bradykinin-mediated
epicardial vasodilation was similar in controls and patients
with risk factors (p 5 0.3 by ANOVA between groups [Fig.
3]). There was no correlation between the epicardial coro-
nary dilator responses to ACH and BK (r 5 0.06, p . 0.5
for both doses of BK). Acetylcholine-induced coronary
epicardial vasomotion was heterogenous even within the
same vessel. Therefore, epicardial responses were compared
by segments rather than by individual patients. Seventy-six
segments constricted (by 10.4 6 0.9% compared with
baseline), and an equal number of segments dilated (7.3 6
0.8%), with ACH. Both doses of BK produced similar
dilation in segments that constricted and those that dilated
with ACH. At the 4 mg/min dose, BK induced 13.1 6 1.4%
dilation in the segment that constricted and 11.2 6 1.3%
dilation in the segments that dilated with ACH (p 5 0.3).
Sodium nitroprusside-mediated epicardial vasodilation was
also similar between the two groups; 18.9 6 1.8% and
19.5 6 1.5%, respectively (p 5 0.8).
Effect of L-NMMA on the responses to ACH and BK.
L-NG monomethyl arginine significantly increased mean
BP from 104 6 3 to 110 6 4 mm Hg, p , 0.001. At rest,
L-NMMA produced epicardial and microvascular constric-
tion; coronary vascular resistance was 14 6 3.6% higher
(p 5 0.02), and epicardial diameter was reduced by 3.9 6
1% (p , 0.001, Fig. 4). L-NG monomethyl arginine also
suppressed epicardial and coronary microvascular responses
Figure 3. Effect of risk factors on bradykinin-induced coronary epicardial
dilation (measured as % change in diameter) and microvascular dilation
(measured as % change in resistance). No difference in responses between
risk groups by analysis of variance.
Figure 4. Bradykinin- (left) and acetylcholine- (right) mediated microvascular (top) and epicardial (bottom) vasomotion before (control solid circles with
solid lines) and after L-NMMA (open circles with dashed lines, n 5 20). *p 5 0.03, **p 5 0.003, ***p , 0.001 comparing control with L-NMMA.
L-NMMA 5 L-NG monomethyl arginine.
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to ACH and to the low dose of BK (62.5 ng/min).
However, at the 4 mg/min dose of BK, epicardial and
microvascular responses were not inhibited by L-NMMA
(Fig. 4).
Flow-mediated epicardial vasomotion during pacing.
During pacing 20 epicardial coronary artery segments con-
stricted (25.1 6 1%, abnormal response) and 30 dilated
(9.6 6 1%, normal response). Bradykinin-mediated epicar-
dial dilation was diminished in segments that constricted
abnormally with pacing compared with segments that di-
lated normally during pacing (p 5 0.027, Fig. 5). By
contrast, ACH-mediated epicardial changes were similar in
segments that constricted (0.2 6 2%) compared with those
that dilated (20.5 6 3%, p 5 0.8) with pacing. Similarly,
epicardial dilation with SNP was similar in the constricting
and dilating segments: 19 6 3% and 20 6 3%, respectively
(p 5 0.9).
There was no correlation between pacing-induced coro-
nary microvascular vasodilation and the responses to either
ACH, BK or SNP.
Serum ACE levels, ACE gene polymorphism and the
response to ACH and BK. The median serum ACE level
in our group was 9.9 U/ml. There was a correlation between
serum ACE levels and the epicardial vasodilator response to
BK (4 mg/min); r 5 20.3, p , 0.001. We, therefore,
divided patients into those with a high ACE level (.
median value, mean 14.4 6 0.6 U/ml, n 5 30) and the
remaining patients with low ACE levels (# median, mean
6.7 6 0.4 U/ml, n 5 32, Fig. 6). Epicardial vasodilation
with BK, especially at the higher dose, was greater in
patients with lower ACE levels, and vice versa (p 5 0.016,
ANOVA, Fig. 6).
Because serum ACE levels are at least partly determined
by the ACE I/D polymorphism (r 5 20.5, p 5 0.0001,
ACE level vs. I/D genotype) and there was a weak but
significant correlation between the epicardial response to
BK (4 mg/min) and ACE genotype (r 5 0.2, p 5 0.02), we
investigated the impact of this genotype on the vascular
responses to BK. Vasodilation with BK at the 4 mg/min
dose was lower in patients with the DD genotype (7.4 6
1.9%) compared with those with the II genotype (14.9 6
2.9%, p 5 0.03), with the ID genotype subset having an
intermediate response (13.1 6 1.3%). The dose-response
curve with BK demonstrated reduced vasodilation in the
DD patients compared with the rest, with the difference
approaching statistical significance (p 5 0.06, ANOVA,
Fig. 6).
There was no relationship between coronary epicardial
and microvascular vasodilation with ACH, or the microvas-
cular dilation with BK and either the serum ACE levels or
the ACE I/D genotype.
DISCUSSION
The first major finding of the study was that the presence of
risk factors for atherosclerosis was not accompanied by
impairment of BK-dependent epicardial or microvascular
dilation. Although there was a correlation between micro-
vascular responses with the two agonists, there was no
correlation between the epicardial responses to ACH and
BK; segments with a constrictor response to ACH had
vasodilation in response to BK that was similar to segments
that dilated with ACH. These findings indicate that injury
to the vascular endothelium by conventional risk factors, or
Figure 5. Bradykinin-induced coronary epicardial dilation in segments that
constricted (n 5 20) and those that dilated (n 5 30) with pacing. The
difference between responses was compared using analysis of variance.
Figure 6. (Top panel) Bradykinin-mediated epicardial vasomotion in
patients with serum ACE levels . median value of 9.9 U/ml (high ACE,
n 5 30) compared with those with levels below median (low ACE, n 5
32). (Lower panel) Bradykinin-mediated epicardial vasomotion in patients
with DD (n 5 13) genotype compared with patients with the ID or II
genotypes (n 5 49). The comparison between groups by analysis of
variance. ACE 5 angiotensin-converting enzyme.
1471JACC Vol. 36, No. 5, 2000 Prasad et al.
November 1, 2000:1467–73 Coronary Kinin Receptor Function
by atherosclerosis itself, may be receptor-specific, involving
the muscarinic receptor and its regulatory pathways, with
relative sparing of the kinin receptor and its pathways.
Second, abnormal epicardial vasomotion during physio-
logic stress, measured as constriction during pacing, is
associated with a depressed response to BK. By contrast,
ACH responses were similar in segments that dilated
compared with those that constricted with pacing, suggest-
ing that abnormal reactivity of epicardial coronary arteries
during physiologic stress is better represented by a pharma-
cologic probe such as BK.
Third, ACH and low-dose BK-mediated vasodilation
was inhibited by L-NMMA, indicating the contribution of
NO to these responses. However, high-dose BK responses
were unchanged with L-NMMA, demonstrating the con-
tribution of factors independent of NO to BK-mediated
coronary vasodilation at higher doses.
Finally, our data illustrates the crucial role of ACE, the
enzyme involved in the metabolism of BK, in determining
the responses to BK; patients with higher vascular ACE
activity, segregated either by serum ACE levels or by the
presence of the ACE DD genotype, had impaired epicardial
responses to BK.
Impact of risk factors for endothelial dysfunction on
vascular responses to BK. Blood vessels from hypercho-
lesterolemic animals and atherosclerotic human subjects
have reduced NO activity under basal conditions and
impaired reactivity to some endothelium-dependent vaso-
dilators, including ACH, 5-hydroxytryptamine and sub-
stance P, but not to others such as BK, adenosine diphos-
phate, norepinephrine and A23187 (14–16). Similarly,
ACH-mediated, but not BK-mediated, vasodilation is de-
pressed in hypercholesterolemia (17). In patients with vari-
ant angina, intact coronary epicardial responses to BK were
reported in segments that constricted with ACH (18). Our
finding that coronary epicardial and microvascular dilation
in response to BK is preserved in patients with risk factors
for atherosclerosis or mild atherosclerosis is consistent with
these studies. However, in significantly stenosed segments
of coronary arteries, BK-mediated vasodilation appears to
be reduced, indicating that kinin receptor function becomes
impaired only in advanced atherosclerosis (18).
A progressive impairment of microvascular dilation in
response to ACH compared with controls was observed
with increasing exposure to conventional risk factors, a
finding previously noted in the epicardial coronary circula-
tion (19). There was a weak significant correlation between
microvascular responses to BK and ACH, though unlike
ACH, the microvascular responses with BK did not corre-
late with the presence of risk factors. Furthermore, segments
that constricted with ACH, a response that is considered to
be a hallmark of conductance vessel endothelial dysfunction,
did not respond differently with BK when compared with
segments that dilated with ACH. Thus, our findings
suggest that mild atherosclerosis or its risk factors impair
muscarinic receptor function with an uneven effect on
endothelial kinin receptors, a finding that was not observed
in a recent study of patients with hypercholesterolemia and
hypertension (20). We analyzed coronary vascular responses
in subsets of patients with either hypertension (n 5 10) or
hypercholesterolemia (n 5 10) without any other risk
factors and found no differences in epicardial vasomotion
with BK compared with controls.
Potential mechanisms. First, ACH and BK act not only
through different receptors but also through distinct intra-
cellular second messenger pathways. Pertussis toxin, a spe-
cific inhibitor of the intracellular membrane-bound Gi
protein, selectively impairs the response to muscarinic ago-
nists without influencing responses to BK, indicating that
the B2 receptor is not coupled with the Gi protein (21,22).
Studies have suggested that BK responses are probably
mediated, at least in part, by the pertussis toxin insensitive
Gq protein-dependent signal transduction pathway. Exper-
imentally, endothelial dysfunction is associated: 1) with
selective impairment of Gi but not Gq protein function (23)
and 2) with decreased expression with Gi proteins in
atherosclerotic human epicardial coronary arteries (24).
Second, a significant component of BK-mediated dilation is
from non–NO endothelium-derived relaxing factors, such as
prostacyclin and endothelium-derived hyperpolarizing factor
(25). This is supported by our observation that BK-mediated,
but not ACH-mediated, dilation was not inhibited by
L-NMMA, suggesting a greater release of non–NO
endothelium-derived relaxing factors with BK. Furthermore, it
is possible that BK-dependent release of prostacyclin and
endothelium-derived hyperpolarizing factor may be preserved
or even upregulated in atherosclerosis (26).
Flow-mediated epicardial vasomotion. Directionally sim-
ilar coronary vasomotor changes have been reported with
physiologic stress and ACH in previous studies (27). How-
ever, most of these investigations have involved segments of
coronary arteries with significant atherosclerotic narrowing.
These segments uniformly constricted with ACH and also
with either mental stress or exercise. In this study most
segments were either angiographically normal or had min-
imal irregularity. We have previously found a weak corre-
lation between atrial pacing-induced microvascular changes
and the response to ACH in patients with relatively normal
epicardial coronary arteries (28). As in this study, that
investigation failed to show a correlation between epicardial
responses during pacing and with ACH.
It is appreciated that shear-induced epicardial coronary
artery vasodilation is endothelium-dependent (3) and may,
in part, be due to stimulation of endogenous BK because it
can be attenuated by the B2 receptor antagonist, icatibant
(4,29). Our finding of reduced BK-mediated vasodilation in
segments that constricted with pacing is, therefore, consis-
tent with these observations. Whether this represents
downregulation of kinin receptors or a defect in their second
messenger pathways needs to be further investigated.
ACE activity and vascular responses. Angiotensin-
converting enzyme is an integral component of the renin-
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angiotensin and kallikrein-kinin systems promoting the
synthesis of angiotensin II and the metabolism of BK. The
ACE I/D polymorphism accounts significantly for interin-
dividual variability in plasma and tissue ACE levels (21).
Our findings indicate that ACE activity determines BK
vascular responses in the epicardial circulation, particularly
at the higher dose (Fig. 6), with the responses lower in
patients with higher circulating ACE levels and those with
the ACE DD genotype. By contrast, ACH responses and
microvascular responses to BK were not influenced by ACE
levels or the ACE I/D polymorphism, a finding also
confirmed in a larger population (30) (ref. 30 published in
this issue of the Journal).
Implications. Bradykinin is an important regulator of hu-
man coronary vascular tone at rest and during conditions of
increased flow (9). In this study we have demonstrated that
BK responses are relatively preserved in patients with risk
factors for atherosclerosis or mild angiographic atheroscle-
rosis. Because effective inhibitors of BK degradation are
available in the form of ACE inhibitors and neutral endo-
peptidase inhibitors, it is possible that enhancing endoge-
nous BK activity with these drugs may reverse the abnor-
malities of coronary reactivity and endothelial dysfunction
observed in patients with atherosclerosis and its risk factors.
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